Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > FDA approves Novartis drug

<< Previous

Bullboard Posts

Next >>

Comment by Yajneon Mar 24, 2022 10:49pm

371 Views

Post# 34544003

RE:RE:FDA approves Novartis drug

I like those numbers enrique. Simple math suggests that TLT would be valued at over $12 with similar metrics for MC under this deal. Then there are all the other advantages that TLT's ACT offers. The Novatis purchase provides what should be a minimum baseline for valuation with considerable (multiples!!) upside from that. So, expecting something (multiples) far north of $12 for my shares. GLTA

enriquesuave wrote:
Also here https://www.biopharmadive.com/news/novartis-fda-approval-pluvicto-prostate-cancer-endocyte/620973/

enriquesuave wrote: Which Novartis paid $2.1 Billion USD from Endocyte I believe about 2 years ago. Endocyte went from $50 Million MC to $2.1 Billion buy out within a year after good PH2 data if I remember. So a 42 bagger in the span of 12 months for a less appealing drug with less efficacy IMo albeit for a different indication. How much will we go up if data is what we hope for?

https://www.medpagetoday.com/hematologyoncology/prostatecancer/97852?xid=nl_mpt_DHE_2022-03-24&eun=g1440998d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Evening%202022-03-24&utm_term=NL_Daily_DHE_dual-gmail-definition